151
Participants
Start Date
January 1, 2005
Primary Completion Date
August 1, 2008
Study Completion Date
August 1, 2008
azacitidine
"Azacitidine is administered subcutaneously~Total of 18 cycles on treatment or early discontinuation."
Western Pennsylvania Cancer Institute, Pittsburgh
Washington Cancer Institute, Washington D.C.
Virginia Oncology Associates - Lake Wright Cancer Center, Norfolk
Florida Cancer Institute, New Port Richey
Cancer Centers of Florida, P.A., Ocoee
The Sarah Cannon Research Institute, Nashville
McLeod Cancer and Blood Center, Johnson City
Greater Dayton Cancer Center, Kettering
Central Indiana Cancer Centers, Indianapolis
Great Lakes Cancer Institute Breslin Cancer Center, Lansing
Avera Cancer Institute Leukemia-Bone Marrow Transplant Center, Sioux Falls
Oncology Services of Aberdeen, Aberdeen
Joliet Oncology-Hematology Associates, Ltd., Joliet
The Center for Cancer Care and Research, St Louis
Hematology & Oncology Specialists LLC, Metairie
Texas Cancer Center at Medical City, Dallas
Texas Oncology, P.A., Bedford
Texas Oncology, PA, Fort Worth
Cancer Care Centers of South Texas - HOAST, San Antonio
San Antonio Tumor & Blood Clinic, Fredericksburg
Rocky Mountain Cancer Centers, LLP, Denver
Cancer Center of Colorado Springs, The Oncology Clinic, PC, Colorado Springs
Tower Cancer Research Foundation, Beverly Hills
Comprehensive Blood and Cancer Center, Research Department, Bakersfield
Puget Sound Cancer Center, Edmonds
Puget Sound Cancer Center, Seattle
Highline Medical Oncology, Burien
Northwest Cancer Specialists, P.C., Vancouver
Cancer Care Northwest, Spokane
Oncology/Hematology Associates of Central Illinois, PC, Peoria
Hackensack University Medical Center, Hackensack
Lead Sponsor
Celgene
INDUSTRY